Chemo list ?

[TriciaK]

I think there is a list somewhere of different chemos---if so would like to study them. I have not had a lot of experience with chemos, especially considering I have been fighting breast cancer for 25 years---first in rt. breast (1985), then spine (1990), then her2 in rt. lung (2004) and now again same place. I only had chemo (navelbine) with herceptin in 2004, which worked very well with no side effects. Now this time, navelbine had weird side effects, so had to stop it. The first gemzar had no side effects but second had really bad rash, though it lowered the ca27-29. As I posted here earlier, my oncologist is trying to decide what to try next, maybe even Gemzar again with allergy meds. I really appreciated the suggestions I received. If you know of a list of chemos I would appreciate being able to do some more research. It is a little urgent because the MRI shows the nodule is growing. Thank you all for help, suggestions, and good thoughts. Hugs, TriciaK

[sassy]

Tricia,

http://her2support.org/her2-breast-cancer/chemo-drugs

This is a link to our chemo drug list. It has not been updated since this time last year, so there may be a few new ones not listed. This may not have as much in depth info as you would like, but may give you a start. If I can help you find additional drugs or more detailed info about a drug, please PM me and I will see what I can do.

[tricia keegan]

I don't have advice Tricia but hoping your onc finds something to zap this fast for you, sending my good wishes and regards !!x

[Joan M]

Tricia,

Eribulin (halaven) is a drug approved by the FDA in November for advanced breast cancer. Perhaps this could be an option.

Here's a news article about the drug:

http://www.medicalnewstoday.com/articles/208238.php

Hugs,

Joan

[ElaineM]

I don't have a chemo list, but I am wondering if you and your doctor can negotiate about the dose or taking the drug with a different schedule. Sometimes a doctor will reduce the dose a little or give the drug every other week instead of every week if the drug appears to be working, but the patient is having alot of side effects.
There may also be other chemos you haven't tried yet.
There are alot of new drugs being tested that will be available in the not so distant future. Several of our members have tried T DM1 or are trying Halaven. You might ask them to share their experiences with you.
Have you tried Abraxane? It is Taxol with a less dangerous binder.
It is good to do research about our health problems and what kinds of treatments are available to us, so we can participate in our health care.
Take good care of yourself.

[ElaineM]

Here is another list.

http://www.breastcancer.org/treatmen.../medicines.jsp

[Jackie07]

Crit Rev Oncol Hematol. 2011 Feb 15. [Epub ahead of print]
Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives.

El Saghir NS, Tfayli A, Hatoum HA, Dinh P, Awada A.
Breast Center of Excellence, NK Basile Cancer Institute, American University of Beirut Medical Center, PO Box 11-0236, Riad El-Solh 1107 2020, Beirut, Lebanon.
Abstract

Current treatment of metastatic breast cancer (MBC) aims at achieving meaningful clinical responses, improved quality of life, long-term remissions, prolonged survival, and dares to hope for a cure in a small percentage of cases. This article will discuss both consensus and controversies in the management of MBC in the context of the new evolving breast cancer molecular classification.

Hormonal therapy remains the mainstay of management of MBC Luminal A and B. Data is emerging on management of ErbB2-positive HR-positive MBC by combining hormonal manipulation and targeted anti-ErbB2 therapy and has recently received regulatory approval in Europe and USA. The optimal use and duration of single agent or combination chemotherapy is discussed. Data and controversies surrounding the use of newer agents such as nab-paclitaxel, ixabepilone, eribulin, and PARP inhibitors as well as trastuzumab is reviewed. Better understanding of pathophysiology has paved the way for the introduction of newer anti-ErbB2 agents such as lapatinib, pertuzumab, T-DM1 and neratinib. Controversies regarding bevacizumab and anti-angiogenesis are discussed. Bisphosphonates have significantly reduced skeletal related events and made significant improvements in the quality of life of patients with MBC. Newer anti-RANK Ligand antibodies show promising results.

Significant advances in the understanding of molecular biology of breast cancer have been made and should lead to an improvement in the outcome of MBC. More possibilities of cure can become an attainable goal in the near future.

[ErbB2 = Her2]

More possibilities of cure can become an attainable goal in the near future.